Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metabolic Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43858   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Study title: J Nucl Med. 2005 Apr;46(4):560-6. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. Ribeiro MJ, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, Dollé F, Nihoul-Fékété C, Syrota A, Brunelle F.
    Active substance: FLUDEOXYGLUCOSE
    Study summary document link (including results):
    View full study record
    Document reference: 28106
    Study title: Diabetes Care. 2001 Mar;24(3):555-60. Blood pressure does not rise before the onset of microalbuminuria in children followed from diagnosis of type 1 diabetes. Oxford Regional Prospective Study Group. Schultz CJ, Neil HA, Dalton RN, Konopelska Bahu T, Dunger DB; Oxford Regional Prospective Study Group.
    Active substance: FLUDEOXYGLUCOSE
    Study summary document link (including results):
    View full study record
    Document reference: 28171
    Study title: An open-label, multicenter, single-dose study to evaluate the pharmacokinetics of glimepiride (Amaryl®) in pediatric patients with type 2 diabetes mellitus - Sponsor Sanofi - 26/02/2004
    Active substance: GLIMEPIRIDE
    Study summary document link (including results): Glimepiride-Study 2.pdf
    View full study record
    Document reference: 28971
    Study title: Glimipiride versus Metformin as Monotherapy in Paediatric Subject with Type 2 Diabetes Mellitus : A Single Bind Comparaison Study - sponsor sanofi - 15/11/2004
    Active substance: GLIMEPIRIDE
    Study summary document link (including results): Glimepiride-Study 1.pdf
    View full study record
    Document reference: 28972
    Study title: Effects of renal failure and metabolic diseases upon bone scanning in children.Schumichen C. Annales de Radiologie 1983 26(6):498-504
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 48758
    Study title: Hendriksz-C-J, Preece-M-A, Chakrapani-A. Department of Clinical Inherited Metabolic Disorders, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK. Successful pregnancy in a treated patient with biotinidase deficiency. Journal of inherited metabolic disease, {J-Inherit-Metab-Dis}, 2005, vol. 28, no. 5, p. 791-2, ISSN: 0141-8955.Hendriksz-C-J, Preece-M-A, Chakrapani-A. Department of Clinical Inherited Metabolic Disorders, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK. Successful pregnancy in a treated patient with biotinidase deficiency. Journal of inherited metabolic disease, {J-Inherit-Metab-Dis}, 2005, vol. 28, no. 5, p. 791-2, ISSN: 0141-8955.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22596
    Study title: Lee WT, Leung SS, Wang SH, Xu YC, Zeng WP, Lau J, Oppenheimer SJ, Cheng JC. Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. Am J Clin Nutr. 1994 Nov; 60(5):744-50. Lee WT, Leung SS, Wang SH, Xu YC, Zeng WP, Lau J, Oppenheimer SJ, Cheng JC. Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. Am J Clin Nutr. 1994 Nov; 60(5):744-50.
    Active substance: CALCIUM CARBONATE
    Study summary document link (including results):
    View full study record
    Document reference: 23155
    Study title: A randomized double-blind study evaluating the safety, tolerability and efficacy of SMOF 20% compared to Intralipid in premature infants
    Active substance: REFINED SOYBEAN OIL; MEDIUM CHAINED TRIGLYCERIDES; REFINED OLIVE OIL; FISH OIL
    Study summary document link (including results):
    View full study record
    Document reference: 40152
    Study title: A randomized double-blind study of safety and efficacy of SMOF 20% vs. Intralipid 20% in infants and children requiring long-term parenteral nutrition
    Active substance: REFINED SOYBEAN OIL; MEDIUM CHAINED TRIGLYCERIDES; REFINED OLIVE OIL; FISH OIL
    Study summary document link (including results):
    View full study record
    Document reference: 40151
    Study title: Acid-Base status in dietary treatment of phenylketonuria
    Active substance: NUTRIENTS WITHOUT PHENYLALANINE
    Study summary document link (including results):
    View full study record
    Document reference: 32725
    Study title: Are tablets a practical source of protein substitute in phenylketonuria?
    Active substance: NUTRIENTS WITHOUT PHENYLALANINE
    Study summary document link (including results):
    View full study record
    Document reference: 32726
    Study title: Mineral and trace – metal Balances in Children receiving normal and synthetic diets
    Active substance: NUTRIENTS WITHOUT PHENYLALANINE
    Study summary document link (including results):
    View full study record
    Document reference: 32723
    Study title: A randomised, multicenter, double-blind trial of Sandostatin LAR Depot (40 mg) versus saline-control in the treatment of pediatric hypothalamic obesity
    Active substance: OCTREOTIDE
    Study summary document link (including results): Novartis Octreotide_Sandostatin LAR Study B2403_31Aug2011.xls
    View full study record
    Document reference: 32741
    Study title: A randomized, multicenter, double-blind trial of Sandostatin LAR Depot (40 mg) versus saline-control in the treatment of pediatric hypothalamic obesity
    Active substance: OCTREOTIDE
    Study summary document link (including results): Novartis Octreotide_Sandostatin LAR Study B2403E1_31Aug2011.xls
    View full study record
    Document reference: 32742
    Study title: A randomized, multicenter, double-blind trial of Sandostatin LAR Depot (40 mg) versus saline-control in the treatment of pediatric hypothalamic obesity
    Active substance: OCTREOTIDE
    Study summary document link (including results):
    View full study record
    Document reference: 32743
    Study title: "Contribution to recalcification therapy in pediatric medicine", Talavera R., Acta Pediatrica Espanola, 1962, 1-25 "Contribution to recalcification therapy in pediatric medicine", Talavera R., Acta Pediatrica Espanola, 1962, 1-25
    Active substance: OSSEIN HYDROXYAPATITE COMPOUND
    Study summary document link (including results): Ossopan nr5.xls
    View full study record
    Document reference: 47718
    Study title: "Monitoring the whole bone-recalciferous therapy", Martin-Santana J., Archivos de Pediatria, 1966, 31(94): 33-44"Monitoring the whole bone-recalciferous therapy", Martin-Santana J., Archivos de Pediatria, 1966, 31(94): 33-44
    Active substance: OSSEIN HYDROXYAPATITE COMPOUND
    Study summary document link (including results): Ossopan nr4.xls
    View full study record
    Document reference: 47717
    Study title: Appendix I to Ephynal (dl-α-tocopherol) NDA pharmacokinetic profile (for Vitamin E) in premature neonated following intramuscular administration
    Active substance: TOCOPHEROL
    Study summary document link (including results):
    View full study record
    Document reference: 47788
    Study title: Kalra V. Vitamin E Administration and Reversal of Neurological Deficits in Protein-Energy Malnutrition. Journal of Tropical Pediatrics 2001; 47: 39-48. Kalra V. Vitamin E Administration and Reversal of Neurological Deficits in Protein-Energy Malnutrition. Journal of Tropical Pediatrics 2001; 47: 39-48.
    Active substance: TOCOPHEROL
    Study summary document link (including results):
    View full study record
    Document reference: 44822
    Study title: Pharmacokinetic profile for vitamin E in premature neonated following intramuscular administration
    Active substance: TOCOPHEROL
    Study summary document link (including results):
    View full study record
    Document reference: 44823
    Study title: Tolerability and acceptability of Ro 01-4065/342, EPHYNAL effervescent tablets
    Active substance: TOCOPHEROL
    Study summary document link (including results):
    View full study record
    Document reference: 47790
    Study title: "Symmetrical Transformation zones in infant rickets (Milkman syndrome?)", Kosenow W., Zeitschrift fur kinderheilkunde, 1951, 69 : 191-206"Symmetrical Transformation zones in infant rickets (Milkman syndrome?)", Kosenow W., Zeitschrift fur kinderheilkunde, 1951, 69 : 191-206
    Active substance: OSSEIN HYDROXYAPATITE COMPOUND
    Study summary document link (including results): Ossopan nr8.xls
    View full study record
    Document reference: 47721
    Study title: "The influence of a whole-bone preparation on the growth of dystrophic children", Gotti D. & Nicolaj P., La clinica Pediatrica, 1951, N°5, 33 "The influence of a whole-bone preparation on the growth of dystrophic children", Gotti D. & Nicolaj P., La clinica Pediatrica, 1951, N°5, 33
    Active substance: OSSEIN HYDROXYAPATITE COMPOUND
    Study summary document link (including results): Ossopan nr7.xls
    View full study record
    Document reference: 47720
    Study title: "The use of powdered raw bone of young animals in children", Cornet-Jacquemoud C., Moderne Probleme der Pediatrie, 1954, 1 : 245-251"The use of powdered raw bone of young animals in children", Cornet-Jacquemoud C., Moderne Probleme der Pediatrie, 1954, 1 : 245-251
    Active substance: OSSEIN HYDROXYAPATITE COMPOUND
    Study summary document link (including results): Ossopan nr6.xls
    View full study record
    Document reference: 47719
    Study title:
    Active substance: PHENYLEPHRINE AND PREDNISOLONE_PHENYEPHRINE ANDZINC SULPHATE
    Study summary document link (including results):
    View full study record
    Document reference: 33954
    Study title: Extract of submission to the UK's Food Standards Agency - P. Holford et al. - 2003 (Journal of Orthomolecular Medicine vol 18) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31482
    Study title: Institute of Medicine (US). Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Food and Nutrition Board. Dietary Reference Intakes for folate, other B vitamins, and choline. - no author - 1999 (Washington DC : National Academy Press) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Institute of Medicine (US). Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Food and Nutrition Board. Dietary Reference Intakes for folate, other B vitamins, and choline. - no author - 1999 (Washington DC : National Academy Press) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised dur...
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31489
    Study title: Treatment of the West syndrome with high-dose pyridoxal phosphate - Y. Ohtsuka et al. - 1987 (Brain Dev vol 9) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Treatment of the West syndrome with high-dose pyridoxal phosphate - Y. Ohtsuka et al. - 1987 (Brain Dev vol 9) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31501
    Study title: Vitamin B6, Magnesium and combined B6-Mg : therapeutic effects in childhood autism - J. Martineau et al. - 1985 (Biol. Psychiatry vol 20) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Vitamin B6, Magnesium and combined B6-Mg : therapeutic effects in childhood autism - J. Martineau et al. - 1985 (Biol. Psychiatry vol 20) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31502
    Study title:
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31503
    Study title: Brief report : an open middle term study of combined vitamin B6 - Magnesium in a subgroup of autistic children selected on their sensitivity to this treatment - J. Martineau et al. - 1988 ( Journal of Autitism and Developmental disorders vol 18) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results): Mg lactate_mg pidolate_pyridoxine chlorhydrate STUDY 246-6-004.xls
    View full study record
    Document reference: 31504
    Study title: Pyridoxine treatment in a subgroup of children with pervasive developmental disorders - S. Kuriyama et al. - 2002 (Developmental Medicine and Child Neurology vol 44) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Pyridoxine treatment in a subgroup of children with pervasive developmental disorders - S. Kuriyama et al. - 2002 (Developmental Medicine and Child Neurology vol 44) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31491
    Study title: Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour - J. Martineau et al. - 1989 (Developmental Medicine and Child Neurology vol 31) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour - J. Martineau et al. - 1989 (Developmental Medicine and Child Neurology vol 31) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31485
    Study title: European Commission Scientific Committee on Food. Opinion of the Scientific Commitee on Food on the tolerable upper intake leval of vitamin B6 (http : // europa.eu.int/comm/food/fs/sc/scf/index en.htlm) - 11/2000 - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31481
    Study title: Treatment of infantile spasms with high-dosage vitamin B6 - J. Pietz et al. - 1993 (Epilepsia vol 34) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Treatment of infantile spasms with high-dosage vitamin B6 - J. Pietz et al. - 1993 (Epilepsia vol 34) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31499
    Study title: Treatment of infantile spasms with high-dosage vitamin B6 : the Heidelberg experience 1989-1999 - J. Scholl et al. - 2000 (Neuropediatrics vol 31) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -Treatment of infantile spasms with high-dosage vitamin B6 : the Heidelberg experience 1989-1999 - J. Scholl et al. - 2000 (Neuropediatrics vol 31) - Publication in MAGNE-B6 Magnesium - pyridoxine Tablet & Oral Solution -Response to questions raised during the renewal process in Estonia -Raphaëlle Pivaty- 04/2004 -
    Active substance: MAGNESIUM LACTATE + MAGNESIUM PIDOLATE + PYRIDOXINE (VIT B6)
    Study summary document link (including results):
    View full study record
    Document reference: 31500
    Study title: Heron-B, Gautier-A, Dulac-O, Ponsot-G. Service de Neurologie Pediatrique, Hopital Saint-Vincent-de-Paul, Paris. Biotinidase deficiency. Progressive encephalopathy curable with biotin. Archives francaises de pediatrie, {Arch-Fr-Pediatr}, Dec 1993, vol. 50, no. 10, p. 875-8, ISSN: 0003-9764.Heron-B, Gautier-A, Dulac-O, Ponsot-G. Service de Neurologie Pediatrique, Hopital Saint-Vincent-de-Paul, Paris. Biotinidase deficiency. Progressive encephalopathy curable with biotin. Archives francaises de pediatrie, {Arch-Fr-Pediatr}, Dec 1993, vol. 50, no. 10, p. 875-8, ISSN: 0003-9764.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22625
    Study title: J.A.R. Calderon: Uso de Pantogar en la terapia contra la caida difusa del cabello y danos estructurales del mismo, 2003
    Active substance: VITAMIN COMBINATIONS
    Study summary document link (including results):
    View full study record
    Document reference: 39401
    Study title: Bates BYC, Evans PH, Sonko BJ, et al. Biochemical indices and neuromuscular function tests in rural Gambian schoolchildren given a riboflavin, or multivitamin plus iron, supplement. British J of Nutr, 1994:72;601-610.Bates BYC, Evans PH, Sonko BJ, et al. Biochemical indices and neuromuscular function tests in rural Gambian schoolchildren given a riboflavin, or multivitamin plus iron, supplement. British J of Nutr, 1994:72;601-610.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45571
    Study title: Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence on a sample of schoolchildren. Lancet, 1988:1;140-3.Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence on a sample of schoolchildren. Lancet, 1988:1;140-3.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45576
    Study title: Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children. Andrianova IV, Sobenin IA, Sereda EV, Borodina LI, Studenikin MI. Ter Arkh. 2003;75(3):53-6.Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children. Andrianova IV, Sobenin IA, Sereda EV, Borodina LI, Studenikin MI. Ter Arkh. 2003;75(3):53-6.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45569
    Study title: Garlic extract therapy in children with hypercholesterolemia. McCrindle BW, Helden E, Conner WT. Arch Pediatr Adolesc Med. 1998 Nov;152(11):1089-94. Garlic extract therapy in children with hypercholesterolemia. McCrindle BW, Helden E, Conner WT. Arch Pediatr Adolesc Med. 1998 Nov;152(11):1089-94.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45570
    Study title: Geltman PL, Meyers AF, Mehta SD, et al. Daily multivitamins with iron to prevent anemia in high-risk infants: A randomized clinical trial. Pediatrics, 2004:114;86-93.Geltman PL, Meyers AF, Mehta SD, et al. Daily multivitamins with iron to prevent anemia in high-risk infants: A randomized clinical trial. Pediatrics, 2004:114;86-93.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45572
    Study title: Immunological and clinical study on therapeutic efficacy of inosine pranobex, Gołebiowska-Wawrzyniak M, Markiewicz K, Kozar A, Derentowicz P, Czerwińska-Kartowicz I, Jastrzebska-Janas K, Wacławek J, Wawrzyniak ZM, Siwińska-Gołebiowska H. Pol Merkur Lekarski. 2005 Sep;19(111):379-82.Immunological and clinical study on therapeutic efficacy of inosine pranobex, Gołebiowska-Wawrzyniak M, Markiewicz K, Kozar A, Derentowicz P, Czerwińska-Kartowicz I, Jastrzebska-Janas K, Wacławek J, Wawrzyniak ZM, Siwińska-Gołebiowska H. Pol Merkur Lekarski. 2005 Sep;19(111):379-82.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45568
    Study title: Linday LA, Tapia-Mendoza J, Shindledecker, RD, et al. Effect of daily cod liver oil and a mutlivtamin-mineral supplement with selenium on upper respiratory tract pediatric visits by young, inner-city, Latino children: randomized pediatric sites. Ann Otol Rhinol Laryngol, 2004:113;891-901.Linday LA, Tapia-Mendoza J, Shindledecker, RD, et al. Effect of daily cod liver oil and a mutlivtamin-mineral supplement with selenium on upper respiratory tract pediatric visits by young, inner-city, Latino children: randomized pediatric sites. Ann Otol Rhinol Laryngol, 2004:113;891-901.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45575
    Study title: Ozkan B, Bereket A, Turan S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr, 2004:163:738-741.Ozkan B, Bereket A, Turan S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr, 2004:163:738-741.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45573
    Study title: Suntaree, RE. Effects of multivitamin and folic acid supplementation in malnourished children. J Med Assoc Thailand, 2003:86;S537-42.Suntaree, RE. Effects of multivitamin and folic acid supplementation in malnourished children. J Med Assoc Thailand, 2003:86;S537-42.
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45574
    Study title: The use of multivitamin-preparations in paediatricsThe use of multivitamin-preparations in paediatrics
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45566
    Study title: Wessely P. Klinischer Erfahrungsbericht. 1985. AKH Wien, Neurologische Univ-Klinik Wessely P. Klinischer Erfahrungsbericht. 1985. AKH Wien, Neurologische Univ-Klinik
    Active substance: VITAMINS
    Study summary document link (including results):
    View full study record
    Document reference: 45567
    Study title: A 12-Month Study to Assess the Safety and Efficacy of Meridia® (sibutramine hydrochloride monohydrate) 10 and 15 mg in Obese Adolescents
    Active substance: SIBUTRAMINE
    Study summary document link (including results): Sibutramine-SB238.pdf
    View full study record
    Document reference: 47621
    Study title: A randomised, placebo controlled, doubly blind study of the effect of sibutramine on the treatment of obese adolescents with a recommended diet and exercise plan followed by a sibutramine-free period (SB116)
    Active substance: SIBUTRAMINE
    Study summary document link (including results): Sibutramine-SB116.pdf
    View full study record
    Document reference: 47620
    Study title: An open-label, single dose, pharmacokinetic study of sibutramine and its metabolites in obese adolescents.
    Active substance: SIBUTRAMINE
    Study summary document link (including results): Sibutramine-SB240.pdf
    View full study record
    Document reference: 47622
    Study title: Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes
    Active substance: SIBUTRAMINE
    Study summary document link (including results): sibutramine-danielsson.xls
    View full study record
    Document reference: 48136
    Study title: Use of Sibutramine in Obese Mexican Adolescents: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial
    Active substance: SIBUTRAMINE
    Study summary document link (including results): sibutramine-garciamorales.xls
    View full study record
    Document reference: 48137
    Study title: A 30-Week, Forced-titration and Randomised, Crossover, Multicentre, Multinational Trial to Evaluate the Efficacy and Safety of rosuvastatin and Atorvastatin in Subjects with Homozygous Familial Hypercholesterolaemia (4522IL/0054): Full Report of the First 18 Weeks (forced-titration) and Last 12 Weeks of Treatment (crossover period) for Efficacy and for Safety
    Active substance: ROSUVASTATIN CALCIUM
    Study summary document link (including results): Study 4522IL0054_CSR Synopsis.pdf
    View full study record
    Document reference: 47886
    Study title: Pharmacokinetics of Rosuvastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia (4522IL/0086)
    Active substance: ROSUVASTATIN CALCIUM
    Study summary document link (including results): Study 4522IL0086_CSR Synopsis.pdf
    View full study record
    Document reference: 47885
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 12:54:00 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA